Compare ARMOUR Residential REIT, Inc. (ARR) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Heron Therapeutics Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.94 (market cap $2.11B), while Heron Therapeutics Inc trades at $0.4 (market cap $79.52M). The key difference: ARMOUR Residential REIT, Inc. is far larger — about 26.5× Heron Therapeutics Inc's market cap, and ARMOUR Residential REIT, Inc. pays a 16.89% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ARR | HRTX | |
|---|---|---|
Market Cap | $2.11B | $79.52M |
Sector | Financials | Health |
52-Week High | $19.12 | $2.18 |
52-Week Low | $14.05 | $0.39 |
Dividend Yield | 16.89% | — |
Enterprise Value | — | $177.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $17.05, down 0.23% today, with a neutral technical signal and bullish moving averages. The stock shows a low P/E of 6.85 and P/B of 0.9, indicating potential undervaluation, while recent earnings beat expectations in Q1 2026. Dividend payments remain steady at $0.24 per share, supporting income appeal. Revenue for 2025 was $332M with a net income margin of 97.2%, though cash flow trends show volatility in investing activities.
Outlook is mixed: analyst consensus is a $18.50 price target with 20% buy ratings, but risks include volatile earnings and high cash flow swings. The stock offers value and yield, yet requires caution due to operational inconsistencies and market sentiment leaning hold.
HRTX trades at $0.4144, down 3.29% today, with a bearish technical signal from moving averages. The company reported Q1 2026 revenue of $154.9M with a net loss of $20.2M, missing EPS expectations. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 94.7% buy ratings. Recent news highlights patent litigation developments and management's reaffirmed full-year guidance despite seasonal headwinds.
The stock faces fundamental challenges with negative earnings and cash flow, but strong analyst support and patent protection for key products provide potential upside. Key risks include ongoing operational losses and competitive pressures in the biotechnology sector. The current valuation at 0.46 P/S suggests potential if the company can achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
